TLR9 Antibody
- Known as:
- TLR9 Antibody
- Catalog number:
- XW-7626
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- TLR9 Antibody
Related genes to: TLR9 Antibody
- Gene:
- TLR9 NIH gene
- Name:
- toll like receptor 9
- Previous symbol:
- -
- Synonyms:
- CD289
- Chromosome:
- 3p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-27
- Date modifiied:
- 2016-10-05
Related products to: TLR9 Antibody
Related articles to: TLR9 Antibody
- Dendritic cells (DCs) orchestrate antitumor immunity by integrating signals from the tumor microenvironment to prime effective T cell responses. Many tumors display altered glycosylation patterns, including tumor-associated carbohydrate antigens (TACAs) such as the Tn antigen (GalNAcα1--Ser/Thr); yet how these structures influence DC function is not well defined. Here, we investigated how Tn-bearing glycoconjugates modulate DC activation and shape adaptive immunity. Bone marrow-derived DCs (BMDCs) efficiently internalized fluorescently labeled Tn-glycoconjugates, whereas uptake of non-glycosylated counterparts was negligible. Although Tn-glycoconjugates alone did not induce DC maturation, co-stimulation with the Toll-like receptor 9 (TLR9) agonist CpG markedly increased CD86 expression and the secretion of IL-12/23p40 and IL-6, with the multivalent construct MAG:Tn3-PV eliciting the strongest response. These conditioned BMDCs promoted strong IFN-γ production by allogeneic splenocytes, consistent with a Th1-polarizing phenotype. Mechanistically, both uptake and CpG-enhanced activation required the C-type lectin receptor MGL2, as blockade of MGL or competition with GalNAc abrogated glycoconjugate uptake and CpG-enhanced cytokine induction. Pharmacological inhibition revealed that MGL2 signaling synergizes with TLR9 through the Syk-Raf-1-NF-κB axis. , mice immunized with DCs conditioned with Tn-glycoconjugate- plus CpG displayed enhanced splenocyte proliferation, increased IFN-γ secretion, and elevated cytotoxic activity without IL-10 induction, confirming a Th1-skewed response. Collectively, these findings identify MGL2 as a critical mediator of Tn-glycoconjugate sensing and unveil a synergistic C-type lectin receptor (CLR)-TLR9 cross-talk that amplifies DC maturation and cytotoxic immunity. This study provides mechanistic insight into how specific glycan-lectin interactions fine-tune innate receptor signaling, highlighting the potential of Tn-based glycoconjugates as immunomodulatory tools for vaccine design and cancer immunotherapy. - Source: PubMed
Publication date: 2026/05/11
Chiale CarolinaBay SylvieGanneau ChristelleFreire Teresa - Endosomal toll-like receptors (TLRs), such as TLR7 and TLR9, are key mediators of autoimmunity. Systemic lupus erythematosus (SLE or lupus) and SjD are distinct diseases that are both characterized by heightened activation of TLR7 and TLR9 signaling networks that serve as potent modulators of chronic inflammation. This review will provide an overview of the role of these receptors in lupus and SjD, with a focus on recent mechanistic insights in the field. We will compare and contrast the roles of TLR7 and TLR9 in lupus and SjD, with a focus on the importance of B cell activation in disease. Moreover, we will discuss differences observed in sex-biased organ-specific disease manifestations. Finally, we will review current and emerging therapies that target endosomal TLR pathways and discuss their utility for treatment of SLE and SjD. - Source: PubMed
Publication date: 2026/04/23
Biswas ShetaKramer Jill M - The efficient delivery of CpG oligodeoxynucleotides (CpG ODN) adjuvants is constrained by the limited endosomal escape capability of lipid nanoparticles (LNPs). To evaluate this critical parameter, we constructed an escape evaluation platform that integrates serum protein corona simulation, a biomimetic phospholipid bilayer barrier, and pH regulation. This platform enables quantitative analysis of the transmembrane delivery mechanism of LNP-CpG ODN while overcoming limitations of cellular models for studying carrier-biointerface interactions. Through optimization of the biomimetic membrane formulation, an optimal balance between high vesicle stability (PDI < 0.18) and membrane fusion activity was achieved. Furthermore, a safer and more efficient preparation workflow was established by replacing chloroform with dichloromethane and eliminating the vacuum-drying step. Importantly, the results reported here identify the pH 6.0 microenvironment, which simulates late endosomal conditions, as the critical functional window for escape, with its efficiency showing a significant positive correlation with TLR9 pathway activation intensity ( = 0.8978, < 0.0001). Overall, this work establishes a dual-parameter correlation framework linking escape efficiency to immune activity, providing a new paradigm for the rational design and optimization of LNP delivery systems. - Source: PubMed
Publication date: 2026/05/05
Cui WenyanCheng YongjianChen WenzhongNouredine BehloulHe JingZuo YanYang Yue - Lumpy skin disease (LSD) is a transboundary animal disease that has serious implications for livestock trade and food security. This study aimed to investigate the molecular and immunological determinants of LSD in vaccinated cattle that developed clinical disease (vaccine breakthrough cases), and to identify potential biomarkers to support disease surveillance and control strategies. - Source: PubMed
Publication date: 2026/04/23
Alqhtani Haifa AliMarzok MohamedElsayed Ahmed AGhonaim Ahmed HAlmubarak Adel IElJalii Isam MohamedBabiker HusseinAlameen Ahmed OmerShoukry MoustafaAbdel-Raheem Sherief MEl-Sabagh Ibrahim MHamed Mohamed FSafhi Fatmah AhmedAlzahrani Elham MohammedAteya AhmedKaram Reham - The success of therapeutic cancer vaccines hinges on overcoming the immunosuppressive tumor microenvironment (TME) and activating robust, durable cellular immunity. Here, we engineered a highly translatable vaccine adjuvant delivery system (LNPC) by integrating the Toll-like receptor 9 (TLR9) agonist CpG with the FDA-approved ionizable lipid ALC-0315. This lipid nanoparticle (LNP) architecture establishes a safe, localized immunological depot that completely shields CpG from systemic nuclease degradation. Crucially, it enables the spatiotemporally coordinated co-delivery of physically admixed antigens and features a "smart" pH-responsive mechanism for targeted endosomal payload release. Consequently, LNPC efficiently activates the TLR9/MyD88 signaling pathway, promotes robust dendritic cell maturation, and drives a pronounced Th1-biased polarization. It uniquely induces the massive expansion of polyfunctional CD8 T cells across diverse immunogens. In aggressive B16F10-OVA melanoma and HPV-associated TC-1 tumor models, LNPC-adjuvanted vaccines successfully remodeled the highly suppressive TME, achieving near-complete tumor clearance, significantly prolonged survival, and durable immune memory without inducing off-target systemic toxicity. Ultimately, the LNPC system represents a versatile, highly effective adjuvant platform with substantial clinical translational potential, offering a compelling new strategy for personalized tumor immunotherapy. - Source: PubMed
Publication date: 2026/05/09
Zeng YarongXu JialinHan FengZhang SiboSu RongLi YufangGao RenfeiZhang XiuliZhou LizhiLi TingtingYu HaiZheng QingbingXia NingshaoLi ShaoweiGu Ying